| 中文名称 | 非布索坦 |
|---|---|
| 中文别名 | 非布索坦;2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸;非布司他;非布索坦 GMP;(2R,4R)- (+)-2-(二苯基膦基甲基)-4- (二环己基膦基)-N-(叔丁氧基羰基)吡咯烷;Febuxostat 抑制剂;N-甲基-4-氨基哌啶二氢溴酸盐;非布司他杂质;非布索坦(解热镇痛)药;非布索坦标准品;非布索坦合成技术转让;非布索坦原药;非布索坦杂质;非布索坦杂质(非布司他);高哌嗪;2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-羧酸;非布索坦-A晶型;非布索坦[A晶型];2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸;非布索坦 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸 |
| 英文名称 | Febuxostat |
| 英文别名 | Febuxostat;Tei-6720;2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid;2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic Acid;2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic Acid;TMX 67;Febuxostat impurity;2-(3-Cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic Acid,This product is unavailable;Adenuric;Febuxostat (This product is unavailable in the U.S.);Febuxostat,This product is unavailable;TEI 6720;Uloric;UNII-101V0R1N2E;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid;Atenuri;2-(3-Cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic Acid;Febuxostat 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid; 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carb;Feburic;Febuxostat (Uloric);2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid;2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID;C16H16N2O3S;101V0R1N2E;5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy);BRD-K48367671-001-01-8;5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-;Q-100164;Uloric (TN);Q417296;2-(3-cyano-4-isobutyloxy)-phenyl-4-methyl-5-thiazolecarboxylic acid;AM20090760;AB01274796_03;BDBM50320491;CCG-213303;Febuday;FEBUXOSTAT [WHO-DD];NSC 758874;FD7322;FEBUXOSTAT [INN];BQSJTQLCZDPROO-UHFFFAOYSA-N;SPIRAMYCINADIPATE;Febuxostatum;Goutex;FEBUXOSTAT [EMA EPAR];AKOS015841695;BCP9000679;FEBUXOSTAT [JAN];2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid;D01206;MX-67;M04AA03;SW219283-1;DB04854;CS-0403;2-(3-Cyano-4-isobutoxy-phenyl)-4-me;F0847;HMS3868J03;NCGC00182059-02;NCGC00182059-03;SR-01000940023-2;BC164443;EN300-122360;5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-;SMR002529566;TMX-67;CAS-144060-53-7;HMS3673M21;S1547;MLS004774136;BCP02342;Tox21_113004_1;HMS3655C03;SR-01000940023;GTPL6817;Tox21_113004;HMS3743I09;2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid;SCHEMBL249339;2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;FT-0601639;Donifoxate;NSC-758874;HY-14268;Pharmakon1600-01504286;AB01274796-01;Z1541759499;BCPP000233;FEBUXOSTAT [ORANGE BOOK];WZB81950;PB33929;NS00004138;111GE013;DTXCID1028576;Feburic (TN);thyl-thiazole-5-carboxylic acid;AC-425;FEBUXOSTAT [MART.];BS-1018;AB01274796_02;CHEBI:31596;HMS3264C20;Febuxostat [USAN:INN:BAN];Goturic;Febric;DTXSID8048650;FEBUXOSTAT (MART.);Febuxostat, >=98% (HPLC);CHEMBL1164729;Febuxostat (JAN/USAN/INN);144060-53-7;Febuxostat- Bio-X;MFCD00871598;Febuxostat [USAN];Febuxostat,Uloric, TMX-67;FEBUXOSTAT [MI];FEBUXOSTAT [VANDF];Zurig;MLS006011568;NSC758874;SBI-0653454.0001;BRD-K48367671-001-05-9;BBL036503;BRD-K48367671-001-06-7;STL559020;FEBUXOSTAT? |
| CAS No. | 144060-53-7 |
| 分子式 | C16H16N2O3S |
| 分子量 | 316.37 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学